Immune Profile and Mitotic Index of Metastatic Melanoma Lesions Enhance Clinical Staging in Predicting Patient Survival

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2009 Nov 17

PMID 19915147

Citations 223

Authors

Dusan Bogunovic

David W ONeill

Ilana Belitskaya-Levy

Vladimir Vacic

Yi-Lo Yu

Sylvia Adams

Farbod Darvishian

Russell Berman

Richard Shapiro

Anna C Pavlick

Stefano Lonardi

Jiri Zavadil

Iman Osman

Nina Bhardwaj

Affiliations

Soon will be listed here.

Abstract

Although remission rates for metastatic melanoma are generally very poor, some patients can survive for prolonged periods following metastasis. We used gene expression profiling, mitotic index (MI), and quantification of tumor infiltrating leukocytes (TILs) and CD3+ cells in metastatic lesions to search for a molecular basis for this observation and to develop improved methods for predicting patient survival. We identified a group of 266 genes associated with postrecurrence survival. Genes positively associated with survival were predominantly immune response related (e.g., ICOS, CD3d, ZAP70, TRAT1, TARP, GZMK, LCK, CD2, CXCL13, CCL19, CCR7, VCAM1) while genes negatively associated with survival were cell proliferation related (e.g., PDE4D, CDK2, GREF1, NUSAP1, SPC24). Furthermore, any of the 4 parameters (prevalidated gene expression signature, TILs, CD3, and in particular MI) improved the ability of Tumor, Node, Metastasis (TNM) staging to predict postrecurrence survival; MI was the most significant contributor (HR = 2.13, P = 0.0008). An immune response gene expression signature and presence of TILs and CD3+ cells signify immune surveillance as a mechanism for prolonged survival in these patients and indicate improved patient subcategorization beyond current TNM staging.

Citing Articles

Unveiling ac4C modification pattern: a prospective target for improving the response to immunotherapeutic strategies in melanoma.

Liu J, Zhang P, Wu C, Luo B, Cao X, Tang J J Transl Med. 2025; 23(1):287.

PMID: 40050821 PMC: 11887236. DOI: 10.1186/s12967-025-06297-6.

CDKN2A, a key gene in copper-induced cell death model, influencing melanoma invasion and apoptosis.

Li J, Yang X, Yin C, Li S, Xu Y, Liu B Discov Oncol. 2025; 16(1):246.

PMID: 40014167 PMC: 11867994. DOI: 10.1007/s12672-025-01992-8.

An -Based Biomarker Combination Accurately Predicts Melanoma Patient Survival.

Sanchez-Beltran J, Soler Diaz J, Herraiz C, Olivares C, Cerdido S, Cerezuela-Fuentes P Int J Mol Sci. 2025; 26(4).

PMID: 40004203 PMC: 11855888. DOI: 10.3390/ijms26041739.

Prognostic value of immune biomarkers in melanoma loco-regional metastases.

Hugdahl E, Aziz S, Klingen T, Akslen L PLoS One. 2025; 20(1):e0315284.

PMID: 39883679 PMC: 11781691. DOI: 10.1371/journal.pone.0315284.

Integrating bioinformatics and machine learning to identify AhR-related gene signatures for prognosis and tumor microenvironment modulation in melanoma.

Li Q, Li H Front Immunol. 2025; 15():1519345.

PMID: 39835132 PMC: 11743449. DOI: 10.3389/fimmu.2024.1519345.

References

Mihm Jr M, Clemente C, Cascinelli N . Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest. 1996; 74(1):43-7. View

Jaeger J, Koczan D, Thiesen H, Ibrahim S, Gross G, Spang R . Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res. 2007; 13(3):806-15. DOI: 10.1158/1078-0432.CCR-06-1820. View

Furey T, Cristianini N, Duffy N, Bednarski D, Schummer M, Haussler D . Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics. 2000; 16(10):906-14. DOI: 10.1093/bioinformatics/16.10.906. View

Dave S, Wright G, Tan B, Rosenwald A, Gascoyne R, Chan W . Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004; 351(21):2159-69. DOI: 10.1056/NEJMoa041869. View

Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam B . The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A. 2005; 102(17):6092-7. PMC: 1087936. DOI: 10.1073/pnas.0501564102. View

Francken A, Shaw H, Thompson J, Soong S, Accortt N, Azzola M . The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004; 11(4):426-33. DOI: 10.1245/ASO.2004.07.014. View

Thompson J, Scolyer R, Kefford R . Cutaneous melanoma. Lancet. 2005; 365(9460):687-701. DOI: 10.1016/S0140-6736(05)17951-3. View

Sato E, Olson S, Ahn J, Bundy B, Nishikawa H, Qian F . Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102(51):18538-43. PMC: 1311741. DOI: 10.1073/pnas.0509182102. View

Chen H, Liakou C, Kamat A, Pettaway C, Ward J, Tang D . Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A. 2009; 106(8):2729-34. PMC: 2650334. DOI: 10.1073/pnas.0813175106. View

10.

Mills K . Gene expression profiling for the diagnosis and prognosis of acute myeloid leukaemia. Front Biosci. 2008; 13:4605-16. DOI: 10.2741/3026. View

11.

Clemente C, Mihm Jr M, Bufalino R, Zurrida S, Collini P, Cascinelli N . Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996; 77(7):1303-10. DOI: 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5. View

12.

Vant Veer L, Bernards R . Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 2008; 452(7187):564-70. DOI: 10.1038/nature06915. View

13.

Tibshirani R, Efron B . Pre-validation and inference in microarrays. Stat Appl Genet Mol Biol. 2006; 1:Article1. DOI: 10.2202/1544-6115.1000. View

14.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C . Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313(5795):1960-4. DOI: 10.1126/science.1129139. View

15.

Nahleh Z . Molecularly targeted therapy in breast cancer: the new generation. Recent Pat Anticancer Drug Discov. 2008; 3(2):100-4. DOI: 10.2174/157489208784638794. View

16.

Henry N, Hayes D . Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancer. Oncology (Williston Park). 2007; 21(11):1301-9. View

17.

Irizarry R, Hobbs B, Collin F, Beazer-Barclay Y, Antonellis K, Scherf U . Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4(2):249-64. DOI: 10.1093/biostatistics/4.2.249. View

18.

Brown M, Grundy W, Lin D, Cristianini N, Sugnet C, Furey T . Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc Natl Acad Sci U S A. 2000; 97(1):262-7. PMC: 26651. DOI: 10.1073/pnas.97.1.262. View

19.

Pavlidis P, Lewis D, Noble W . Exploring gene expression data with class scores. Pac Symp Biocomput. 2002; :474-85. View

20.

Attis M, Vollmer R . Mitotic rate in melanoma: a reexamination. Am J Clin Pathol. 2007; 127(3):380-4. DOI: 10.1309/LB7RTC61B7LC6HJ6. View